TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent prior to any study-specific procedures.~* Self-reported active symptoms of OIC at screening (\<3 SBMs/week and experiencing ≥1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks); and Documented confirmed OIC (\<3 SBMs/week on average over the 2-week OIC confirmation period.~* Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies for a minimum of 4 weeks prior to screening for non-cancer-related pain with no anticipated change in opioid dose requirement over the proposed study period as a result of disease progression.~* Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 2-week OIC confirmation period and the 12-week treatment period, and to use only bisacodyl as rescue medication if a BM has not occurred within at least 72 hours of the last recorded BM.~Exclusion Criteria:~* Patients receiving Opioid regimen for treatment of pain related to cancer.~* History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.~* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.~* Other issues to the gastrointestinal tract that could impose a risk to the patient.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral treatment
- 2 (Type: EXPERIMENTAL): Oral treatment
- 3 (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Local Anaesthetic Volume on Axillary Brachial Plexus Block Duration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* ASA 1-3~* Patients aged \>18 years~* undergoing elective upper limb (forearm, wrist or hand) surgical procedures.~Exclusion Criteria~* Contraindications to regional anaesthesia~* Hypersensitivity to amide local anaesthetics.~* Chronic pain~* Language barrier~* Neuromuscular disorders or peripheral neuropathy~* Body mass index \> 35~* History of hepatic and renal insufficiency~* Pregnancy~* Cognitive or psychiatric disorder~* Cardiac conduction abnormality.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 ml of lidocaine 2% with epinephrine (Type: ACTIVE_COMPARATOR): patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
- 30ml of lidocaine 2% with epinephrine (Type: EXPERIMENTAL): patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In general, good physical health as determined by medical history and psychiatric history, suicidality assessment \& physical examination~* Men who are potentially fertile (not surgically \[eg, vasectomy\] or congenitally sterile~* Patients with Huntington's disease (HD): diagnosis of HD and with an onset of HD after 18 years of age~  * Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* The subject has been previously exposed to ionizing radiation or radioactive substances as a result of clinical research or medical treatment in the past 10 years.~* The subject has a counterindication to having an MRI~* History of alcohol, narcotic, or any other substance dependence in the past 2 years~* Additional Exclusion criteria to patients with Huntington's disease:~* The patient has a severe motor impairment that might cause artifacts.~* Patients with a known history of Long QT Syndrome or a first degree relative with this condition.~* Treatment with any investigational product within 6 weeks of screening or patients planning to participate in another clinical study assessing any investigational product during the study.~  * Additional criteria apply, please contact the investigator for more information

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- pridopidine (Type: EXPERIMENTAL): Pridopidine (TV-7820) capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic lumbar spinal stenosis (LSS) primarily caused by dorsal element hypertrophy.~* Prior failure of conservative therapy and Oswestry Disability Index (ODI) score \> 20%.~* Radiologic evidence of lumbar spinal stenosis (LSS), ligamentum flavum hypertrophy (typically \> 2.5 mm), confirmed by pre-op MRI and/or CT.~* Central canal cross sectional area clearly reduced per MRI/CT report.~* If present, anterior listhesis preferred ≤ 5.0mm and deemed stable by Investigator.~* Able to walk at least 10 feet unaided before being limited by pain.~* Available to complete 26 weeks of follow-up.~* A signed Informed Consent Form is obtained from the patient.~* Adults at least 18 years of age.~Exclusion Criteria:~* Prior surgery at intended treatment level.~* Compound fracture with interspinal retropulsion contributing to spinal stenosis.~* Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).~* Disc protrusion or osteophyte formation severe enough to confound study outcome.~* Facet hypertrophy severe enough to confound study outcome.~* Bleeding disorders and/or current use of anti-coagulants.~* Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.~* Epidural steroid administration within prior three weeks (of procedure).~* Inability of the patient to lie prone for any reason with anesthesia support (e.g.chronic obstructive pulmonary disease (COPD), obesity, etc.).~* Metabolic wound healing pathologies deemed by Investigator to compromise study outcomes.~* Dementia and/or inability to give informed consent.~* Pregnant and/or breastfeeding.~* On Workman's Compensation or considering litigation associated with back pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lumbar decompression (Type: OTHER): Percutaneous lumbar decompression with mild® Device Kit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants greater than or equal to (\>=) 18 years of age.~2. Participants must have undergone an orthopedic procedure (that is, total knee or hip replacement, spinal fusion, or reduction of fracture(s) with or without surgical fixation post trauma).~3. Participants must be receiving opioid analgesics (a mu agonist only-not to include agents with mixed mechanisms of action such as tramadol or buprenorphine) after the procedures and be expected to require daily opioid analgesics for at least 7 days post randomization.~4. Participants must be acutely constipated following their orthopedic procedure.~5. Participants must receive all doses of study drug in either hospitals or rehabilitation facilities.~6. Participants must sign an informed consent form.~7. Females of childbearing potential must have a negative pregnancy test and use appropriate birth control throughout the study.~8. Body weight within range of 40 kilograms (kg) - 150 kg (88 - 330 pounds \[lbs\]).~Exclusion Criteria:~1. Participants with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.~2. Participants who received any investigational new drug (experimental) in the previous 30 days.~3. Participants who have received a laxative (for example, lactulose) or an enema within 48 hours prior to the first dose.~4. Participants with constipation not attributed to post procedure opioids.~5. Participants with a history of alcohol or prescription or non-prescription drug abuse within the past 2 years.~6. Female participants who are pregnant or lactating.~7. Participants with a known history of chronic active hepatitis B or hepatitis C virus or human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MNTX (Type: EXPERIMENTAL): Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing to sign informed consent and capable of understanding the features of this clinical trial.~* Willing to keep a weekly diary and undergo observation for 12 months~* Non-pregnant patients 18-55 years of age with MS according to the revised McDonald criteria and meeting the Poser criteria for clinically defined MS.~* EDSS scores of 2·0 to 5·5 points assessed at least 3 months after the last acute attack of MS.~* Must have proof of health insurance in country of residence.~Exclusion Criteria:~* Patients with evidence of active proliferative retinopathy.~* Patients with poorly controlled diabetes mellitus (glycated hemoglobin: HbA1C \> 8.5%).~* Patients with renal insufficiency (Creatinine\> 2.5) or failure.~* Infection as evidenced by white blood cell (WBC) count of \>15,000 k/cumm and/or temperature \> 38 Celsius.~* History of organ transplant.~* History of previous or active malignancy, except for localised cutaneous basal or squamous cell carcinoma or carcinoma in situ of the cervix~* Exercise limiting angina ( Canadian Cardiovascular Society Class 3~* Congestive heart failure (New York Heart Association class 3~* Unstable angina~* Acute ST elevation myocardial infarction (MI) within 1month~* Transient ischemic heart attack or stroke within 1 month~* Severe valvular heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical cord mesenchymal stem cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Participants diagnosed with ulcerative colitis.~2. Participants with moderate ulcerative colitis who satisfy all of the following criteria at Day of enrollment.~   1. Mayo Clinic scores of 6-10 .~  2. Endoscopic subscore greater than or equal to (\>=) 2.~  3. Rectal bleeding subscore \>=1.~3. Participants with inadequate response or intolerant to oral 5-ASA~4. Participants who are capable of providing written informed consent~Major Exclusion Criteria:~1. Participants with extensive detachment of mucosa or deep ulcer.~2. Participants with oral corticosteroid dependency.~3. Participants with a complication of marked reduction of immune function.~4. Participants who were clinically suspected to have a complication of infectious enteritis.~5. Participants with a history or complication of serious infection within 1 year prior to the day of enrollment.~6. Participants with central nervous system (CNS) neurological symptoms.~7. Participants with the following criteria:~   * Serious heart disease~  * Renal impairment~  * Hepatic impairment~8. Participants with a history of serious drug induced allergy with unknown cause.~9. Participants with malignant tumor or those whose treatments were completed in less than 5 years.~10. Participants with apparent psychological signs.~11. Pregnant women, nursing women, women with suspected pregnancy, women who wish to become pregnant during the period from informed consent through to the end of observation/examination at Week 8, and women who do not consent to the use of appropriate birth control methods.~12. Participants who are definitely eligible for surgical intervention such as large bowel perforation, major bleeding, and toxic megacolon syndrome, etc.~13. Participants who are participants of another clinical study including follow-up observation at the time of informed consent.~14. Participants who received another investigational drug within 12 weeks prior to the examinations/observation defined by the protocol.~15. Participants who received investigational drugs in the study of AJM300.~16. Participants determined to be ineligible for participation in this study by the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- AJM300 960mg/dose (Type: EXPERIMENTAL): Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of African American background; self identified~* Patients with stage 2 hypertension defined as MSSBP ≥ 160 mmHg and \< 200 mmHg at Visit 5 (randomization~Exclusion Criteria:~* Office blood pressure measured by cuff (MSDBP ≥ 110 mmHg and/or MSSBP ≥ 200 mmHg)~* Patients on 4 or more antihypertensive medications.~* Patients with uncontrolled hypertension (MSSBP \>180 mmHg) taking more than 1 antihypertensive medication at Visit 1~* Refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg). Therapy with a fixed dose combination of two active substances represent two drugs.~* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Evidence of a secondary form of hypertension, including but not limited to any of the following:~  * coarctation of the aorta~ * hyperaldosteronism~ * unilateral or bilateral renal artery stenosis~ * Cushing's disease~ * polycystic kidney disease~ * pheochromocytoma~* Known Keith-Wagener grade III or IV hypertensive retinopathy.~* History of angioedema due to usage of an ARB or ACE inhibitor.~* History of hypertensive encephalopathy, cerebrovascular accident, transient ischemic attack, heart failure (NYHA Class II-IV), coronary bypass graft surgery (CABG), percutaneous coronary intervention (PCI), unstable angina pectoris, or myocardial infarction in the last 12 months~Other protocol defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren/Amlodipine (Type: EXPERIMENTAL): Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
- Amlodipine (Type: ACTIVE_COMPARATOR): Amlodipine 5mg titrated to 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer~* T1c-3 N0-2a~* Confirmed of hormonal receptor status~* HER2 positive confirmed by IHC 3+ or FISH+~* LVEF \> 50% by echocardiogram or MUGA~* Adequate EKG~* No prior treatment for breast cancer~* PS 0-1~* Required baseline laboratory data WBC \> 4,000/mm3 and Neut \> 2,000/mm3 PLT \> 100,000/mm3 Hb \> 9.0g/dl AST and ALT \< ULNx2.5 T-Bil \< 1.5mg/dl Serum creatinin \< 1.5mg/dl~* Written informed consent~Exclusion Criteria:~* With history of hypersensitivity reaction for important drug in this study~* With history of invasive breast cancer~* Bilateral invasive breast cancer~* Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus~* Positive for HBs antigen and with history of HVB~* With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension~* With severe edema~* With severe peripheral neuropathy~* With severe psychiatric disorder~* Pregnant or nursing women~* Cases who physician judged improper to entry this trial

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel (Type: EXPERIMENTAL): Nab-paclitaxel q3w 260mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* diagnosed RA for \>=3 months prior to first administration of study medication;~* inadequate response or intolerance to \>=1 anti-TNF therapies, alone or in combination with methotrexate;~* if using NSAIDS, analgesics or oral corticosteroids, must be on a stable dose for \>=2 weeks prior to start of study.~Exclusion Criteria:~* other chronic inflammatory diseases;~* use of parental corticosteroids within 4 weeks prior to screening;~* severe heart failure, or severe, uncontrolled cardiac disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete